GlassScriptPhysician profile
Xu L He
NPI 1568773448
$351,127.56
in general payments reported to CMS, 2019-2025
71 companies · $83K in 2025
The $83K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,102 · 2020: $3,118 · 2021: $62K · 2022: $42K · 2023: $79K · 2024: $75K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $163K · Travel and Lodging: $25K · Food and Beverage: $22K · Consulting Fee: $19K · Honoraria: $7,350 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $162,508.05 |
| Travel and Lodging | $25,449.58 |
| Food and Beverage | $22,434.50 |
| Consulting Fee | $19,445.00 |
| Honoraria | $7,350.00 |
| Education | $124.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $79,434.76 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Biohaven Pharmaceuticals, INC. | $57,270.35 | 2020-2021 | |
| Pfizer INC. | $39,429.53 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30,969.02 | 2022 | |
| Idorsia Pharmaceuticals US INC | $23,771.80 | 2022-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $22,645.84 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $18,773.38 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Cequr Corporation | $16,611.71 | 2022-2025 | Cequr Simplicity |
| Medicure Pharma INC. | $9,652.26 | 2023-2025 | Zypitamag |
| Bayer Healthcare Pharmaceuticals INC. | $7,168.81 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,761.45 | 2023-2025 | Rexulti |
| Phadia US INC. | $5,126.96 | 2019-2025 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $4,799.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $3,846.40 | 2019-2024 | |
| Intra-Sana Laboratories | $3,689.40 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,113.09 | 2019-2025 | Jardiance |
| Horizon Therapeutics Plc | $2,032.81 | 2020-2023 | Krystexxa |
| Abbvie INC. | $1,674.33 | 2020-2025 | |
| Novo Nordisk INC | $1,237.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $1,107.71 | 2023-2025 | Korlym |
| Vertex Pharmaceuticals Incorporated | $1,054.26 | 2025 | |
| Abbott Laboratories | $1,009.10 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $932.84 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Mannkind Corporation | $885.62 | 2019-2023 | Afrezza |
| Axsome Therapeutics, INC. | $715.49 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $655.66 | 2019-2025 | Trintellix |
| Allergan, INC. | $646.63 | 2019-2021 | |
| Amarin Pharma, INC. | $645.52 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $644.75 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $553.76 | 2019-2023 | Verquvo, Belsomra |
| Lilly USA, LLC | $540.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Lexicon Pharmaceuticals, INC. | $478.78 | 2023-2024 | Inpefa |
| Arbor Pharmaceuticals, INC. | $370.14 | 2019-2022 | |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Dexcom, INC. | $331.41 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Exact Sciences Corporation | $271.59 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $268.94 | 2024-2025 | Recorlev |
| Braintree Laboratories, INC. | $228.01 | 2019 | |
| Neurocrine Biosciences, INC. | $176.57 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $162.49 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $154.95 | 2019-2025 | Austedo Xr |
| Eisai INC. | $143.49 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $141.83 | 2022-2024 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.78 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $130.96 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $124.78 | 2019 | |
| Vifor Pharma, INC. | $124.32 | 2019 | |
| Hologic Sales and Service, LLC | $117.28 | 2019 | |
| Almatica Pharma LLC | $111.58 | 2021-2022 | |
| Astellas Pharma US INC | $103.67 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.99 | 2024-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $91.85 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $91.54 | 2019-2025 | |
| Scynexis, INC. | $53.84 | 2022 | |
| Exeltis, USA INC. | $47.33 | 2025 | Slynd |
| Ironwood Pharmaceuticals, INC | $45.52 | 2021 | |
| Shield Therapeutics INC | $44.63 | 2025 | |
| Upsher-Smith Laboratories LLC | $40.29 | 2020 | |
| Dermira, INC. | $40.11 | 2020-2021 | |
| Csl Behring | $34.64 | 2025 | Haegarda |
| Ardelyx, INC. | $27.55 | 2024 | Ibsrela |
| Genentech USA, INC. | $27.39 | 2020-2021 | |
| Organon LLC | $26.63 | 2025 | Nexplanon |
| Boston Scientific Corporation | $19.00 | 2021 | |
| Redhill Biopharma INC. | $18.46 | 2021 | |
| Mylan Specialty L.P. | $18.10 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $17.00 | 2019 | |
| Lundbeck LLC | $16.93 | 2024 | Rexulti |
| Alnylam Pharmaceuticals INC. | $15.00 | 2021 | |
| Currax Pharmaceuticals LLC | $14.50 | 2025 | Contrave |
| Azurity Pharmaceuticals, INC. | $13.81 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xu He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.